Article
A SOX2-engineered epigenetic silencer factor represses the glioblastoma genetic program and restrains tumor development
3 Aug 2022
Abstract excerpt
Current therapies remain unsatisfactory in preventing the recurrence of glioblastoma multiforme (GBM), which leads to poor patient survival. By rational engineering of the transcription factor SOX2, a key promoter of GBM malignancy, together with the Kruppel-associated box and DNA methyltransferase3A/L catalytic domains, we generated a synthetic repressor named SOX2 epigenetic silencer (SES), which induces the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
